Trial | NCT00390936  Report issue

Title

A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
Phase I Multiple Ascending Dose Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Japanese Patients With Advanced or Metastatic Solid Tumors

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    13
The purpose of this study is to assess the dose limiting toxicity (DLT) of BMS-582664 and the maximum tolerated dose(MTD) in subjects with advanced or metastatic solid tumors.
Study Started
Oct 31
2007
Primary Completion
Mar 31
2010
Study Completion
Mar 31
2010
Last Update
Jan 25
2011
Estimate

Drug Brivanib

Tablet, Oral, Brivanib 300 mg, 600 mg, 800 mg, 1000 mg, once daily (cycle 1: Day 1, Day 8 - 35), more than 5 weeks depending on response/toxicity

  • Other names: BMS-582664

1 No Intervention

4 dosages

Criteria 

Inclusion Criteria:

Patients must have measurable disease
Documented failure to standard therapies exist, or which are determined to be inappropriate by the investigator
ECOG PS: 0-1

Exclusion Criteria:

Subjects with centrally located squamous cell carcinoma of the lung
No Results Posted